67results about How to "Reduce cravings" patented technology

Disclosed herein is a method for treating depression associated with alcoholism in a patient comprising administering to the patient a pharmacologically effective dose of an opioid antagonist, and a pharmacologically effective dose of at least one drug compound selected from the group consisting of a tricyclic antidepressant, an a-typical antidepressant, and lithium.

A two-stage medicine delivery system provides an initial dose of medicine and a second dose of medicine. The initial and second doses are capable of achieving a rapid pharmacological effect and a prolonged pharmacological effect, respectively. The two-stage medicine delivery system preferably delivers a craving reduction substance, in which case, the rapid and prolonged pharmacological effects include a rapid and prolonged craving reduction. Preferably, the delivery system is a nicotine delivery system which is provided in chewing gum form or lozenge form and which provides the nicotine in a transmucosally absorbable form. The two-stage medicine delivery system preferably releases a buffering agent which increases a pH level in a user's mouth to facilitate absorption of the medicine when the delivery system is placed in the user's mouth. A method of making the medicine delivery system also is provided. The system and apparatus can be adapted to reduce cravings for alcohol, food, drugs (e.g., cocaine, opiates and the like) and tobacco products, especially tobacco products containing nicotine.

The present invention is directed to a combination treatment of an opioid antagonist e.g., naltrexone and a second compound selected from the group consisting of a GABA B agonist, an NMDA antagonist, a serotonin antagonist, and a cannabinoid antagonist is the key to the successful treatment of a brain reward system disorder. A brain reward system, include but are not limited, to pathological gambling, compulsive alcohol consumption, compulsive over-eating and obesity, compulsive smoking, and drug addiction. The compounds and methods of the present invention effectively reduce the cravings, withdrawal symptoms and negative drug side effects associated with a monotherapy. As such, patient compliance is greatly increased, thereby decreasing relapse of a brain reward system disorder.

Embodiments of the invention provide methods for the transdermal delivery of therapeutic agents for the treatment of addictive cravings e.g., nicotine compounds for the treatment of nicotine cravings from tobacco use. An embodiment of a method for such delivery comprises positioning at least one electrode assembly in electrical communication with a patient's skin. The assembly includes a solution comprising a therapeutic agent which passively diffuses into the skin. A dose of agent is delivered from the assembly into the skin during a first period using a first current having a characteristic e.g., polarity and magnitude, to repel the agent out of the assembly. During a second period, a second current having a characteristic to attract the agent is used to retain the agent in the assembly such that delivery of agent into skin is minimized. A dose of agent may be delivered on demand by an input from the patient.

Described here are devices and methods for intussuscepting a portion of stomach tissue. Typically the intussusception is created at a position near, but distal to the gastroesophageal junction, and a pouch capable of storing a volume (from about 0 cc up to about 100 cc) is created proximal the intussuscepted tissue. In this way, the amount of food that may be ingested is reduced, helping to ameliorate GERD symptoms, and aiding in weight loss efforts. Some of the devices described here include an expandable member and at least one suction inlet. In these devices, the expandable member is expanded to create a proximal cavity into which the stomach tissue is pulled (e.g., using suction), thereby creating the intussusception.

The invention provides a method of treating a psychiatric or medical disorder in a mammalian subject, the method comprising administering to the subject an effective amount of an oxytocin receptor agonist (e.g., oxytocin). Optionally, the oxytocin receptor agonist is delivered by intranasal administration. Further provided is a method of increasing social cognition, increasing social functioning, increasing empathy, increasing trust of others, reducing paranoia and/or reducing hostility in a subject with a psychotic disorder, a mood disorder characterized by psychotic features, a personality disorder or a pervasive developmental disorder, the method comprising administering to the subject an effective amount of an oxytocin receptor agonist. The invention also contemplates a method of preventing opioid dependence, opioid tolerance and/or opioid withdrawal symptoms in a subject receiving opioid treatment for pain relief, the method comprising administering to the subject an effective amount of an oxytocin receptor agonist. The invention also provides pharmaceutical compositions comprising an effective amount of an oxytocin receptor agonist and a pharmaceutically acceptable carrier.

A practical high potency anti-craving medication is disclosed which comprises three components: an amino-acid component, a vitamin component, and a mineral component, wherein each component is selected for maximum efficacy in the body of an individual suffering from substance abuse disorder as opposed to the body of a healthy individual. Additionally, the active agents are received by means of a prolonged administration, preferably by means of an IV drip, thus assuring a period of time in which the active agents are present in desired concentrations, and more preferably a prolonged time during which they are simultaneously present in desired concentrations. The agents of each component are also selected so as to allow easy administration of the medication to patients in three vials of medication rather than as a large number of individual vials.

A fast-dissolving film to be placed in the oral cavity of a person includes nicotine, or nicotine analog, with or without menthol, or menthol analog, that can be absorbed through the oral mucosa directly into the person's bloodstream for the purpose of reducing a temporary craving for nicotine during periods when smoking is not possible, or for therapeutic purposes, the film being thin and made from a low-moisture, non-tacky material that becomes dissolved when hydrated and that is sized so that the substrate can be placed in oral cavities of persons. From 0.1 mg to 10 mg nicotine, or a nicotine analog, and, optionally, menthol, or a menthol analog, are added to the substrate, which is then packaged in a flat, sealed container that can be unobtrusively placed into a pocket carried by the smoker, thereby making the container readily accessible to the smoker. During a period of nicotine craving encountered by the smoker when smoking is not possible, the film is removed from the container and placed into the smoker's oral cavity so that it contacts a mucosal membrane in the oral cavity of the smoker to thereby hydrate the substrate. The nicotine is thereby liberated from the film so that it can enter the smoker's bloodstream via the mucosal membrane to thereby temporarily satisfy the smoker's nicotine craving.

Embodiments of the invention provide methods for the transdermal delivery of therapeutic agents for the treatment of addictive cravings e.g., from nicotine. An embodiment of a method for such delivery comprises positioning at least one electrode assembly in electrical communication with a patient's skin. The assembly includes a solution comprising a therapeutic agent which passively diffuses into skin. A dose of agent is delivered from the assembly into skin during a first period using a first current having a characteristic e.g., polarity and magnitude, to repel agent out of the assembly. During a second period, a second current having a characteristic to attract agent is used to retain agent in the assembly such that delivery of agent into skin is minimized. In particular embodiments, a dose of agent may be delivered on-demand using an input from the patient using an inhalation sensing device which mimics an inhaled form of tobacco.

In the treatment of alcoholism, co-treatment with an active agent capable of offsetting unwanted adverse clinical manifestations to the treatment itself, for example, negative drug adverse clinical manifestations, greatly increases patient compliance. Increasing patient compliance, in turn, creates a better success rate and decreased recidivism or relapse. The current invention combines the use of an opioid antagonist with at least one dopamine D2 partial agonist for the treatment of alcoholism. Suitable dopamine D2 partial agonists are aripiprazole and (−)3-(3-hydroxyphenyl)-N-n-propylpiperidine [(−)-3PPP].

A method of dieting includes the steps of reducing the secretion of insulin in the metabolic system of body, reducing the carbohydrate from meals, reducing the size of meals, and reducing the sense of hunger and the craving for food. The step of reducing the secretion of insulin includes the step of having protein-intensified meals. The step of reducing the carbohydrate from meals includes the steps of having leafy vegetables and excluding fruits from meals. The step of reducing the size of meals includes the steps of breaking a given meal into multiple servings and having the servings with predetermined interval. The step of reducing the sense of hunger and the craving for food includes the steps of drinking enough water, excluding spicy foods from meals, and prohibiting exercise. In the final steps, the method of dieting further includes the steps of having balanced meals and excising regularly.

The invention belongs to the field of pharmaceuticals, health-care foods or foods and particularly relates to a composition having face-beautifying and weight-losing effects and a preparation method and application thereof.The composition is prepared from, by weight, 15-60 parts of dietary fibers, 10-30 parts of arabinose, 1-10 parts of kidney bean protein, 0.1-5 parts of L-carnitine, 1-2 parts of chitosan oligosaccharide, 0.01-20 parts of collagen peptide, 0.01-20 parts of soybean oligopeptide and 0.01-5 parts of a guarana extract.According to the composition having the face-beautifying and weight-losing effects, full consideration is given to the composition of the raw materials and the mutual proportion of the raw materials is selected to make the raw materials mutually and proportionally matched and produce the combined action.The composition has the weight-losing effect, can improve the radiance and elasticity of the skin and prevent the phenomenon that the skin loses the elasticity and collapses due to weight losing while losing the weight, and meanwhile plays the face-beautifying and weight-losing effects.

A buprenorphine hydrochloride/naloxone hydrochloride sublingual tablets with low misuse potential , said tablets contain medicinal contents of buprenorphine hydrochloride and naloxone hydrochloride, part by weight thereof is 2:1-6:1, 1) using alcohol to dissolve regulator corrigent and bond of PH of prescription amount for use; 2) grinding main medicine buprenorphine hydrochloride/naloxone hydrochloride, filler and lubricant and sifting out thereof; 3) mixing evenly the prescription amount of buprenorphine hydrochloride/naloxone hydrochloride, filler, bond and disintegrating agent, thereafter adding contents in step 1 to prepare into soft stuff, again making into pellet, drying, sorting out, adding lubricant again, mixing evenly and pressing into tablet.

The invention discloses a weight-loss formula and a method capable of healthily clearing a body and decomposing fat. The weight-loss formula comprises a body clearing period, a slimming period and a metabolism adjustment period sequentially; each period comprises adjustment of a reasonable dietary structure, supplement of sufficient high-quality vitamin and mineral substances, and guarantee of daily exercise amount and water intake. The invention provides a weight-loss method capable of healthily clearing the body. Through the reasonable dietary structure, the supplement of sufficient vitamin and mineral substances, and the guarantee of daily exercise amount and water intake, the human weight is reduced. According to the method, a hunger gene of a human body is not stimulated, a new slim memory system of the body is established, and a well-managed weight and living habit is formed. The formula and the method has the characteristics of no dieting, no strenuous exercise and no bounce, can be beneficial to effectively improving blood pressure, blood fat and other symptoms while losing weight, and truly realize scientific, safe, healthy and effective weight loss.

A method for enhancing at least one of craving-reduction, mood improvement, avoidance of depression, prevention of weight gain post weight-loss from dieting, reduction of negative side effects produced by anti-appetite drugs and smoke-cessation and promotion of healthy ageing in a person in need thereof, comprising administering a composition to said person, said composition comprising:

• • a) an effective amount of an extract of Cyperus esculentus peel, Cyperus esculentus rhizomes, or a combination thereof;
  • b) an effective amount of mangiferin, norathyriol, or an extract comprising mangiferin or norathyriol; or
  • c) a synergistic combination of (a) and (b).

The composition may comprise a third active ingredient in combination with the Cyperus esculentus extract and mangiferin or norathyriol.

The invention discloses an enzymatic probiotic powder for controlling body weight. The enzymatic probiotic powder is prepared from, by mass, 1-5 parts of comprehensive fruit and vegetable fermentationpowder, 0.5-5 parts of vegetable and fruit plant enzyme powder, 10-40 parts of prebiotics, 10-40 parts of water-soluble dietary fibers, 0.1-1 part of probiotics and 1-40 parts of fruit juice powder.The enzymatic probiotic powder can well casuse a feeling of satiety, reduce the eating desire of drinkers, contain lipolytic enzymes, decompose fat and achieve the effect of controlling the body weight. Meanwhile, the enzymatic probiotic powder can improve the intestinal tract function, promote intestinal tract motility, relieve constipation, accelerate the absorption and metabolism of nutrient substances, and further improve the effect of controlling the body weight.

Administered anticraving compositions are disclosed for treating patients addicted to alcohol comprising an effective amount of at least one alpha-pyrone compound formulated into a physiologically acceptable carrier medium. Additionally, a method of oral administration of the anticraving compounds is disclosed where an effective amount of at least one alpha-pyrone compound is formulated into a wine, beer or distilled spirit where the alcohol has been removed and replaced by one or more kavapyrones.

The invention provides smoking cessation sugar and a preparation method thereof. The smoking cessation sugar is prepared from the following components in percentage by mass: 1 to 7 percent of tobacco powder, 4 to 13 percent of cordate houttuynia powder, 2 to 8 percent of mint powder, 3 to 6 percent of mustard seeds and 70 to 85 percent of xylitol. The smoking cessation sugar can help smokers to effectively give up smoking, effectively prevent and treat various diseases caused by smoking and prevent passive smoking environmental influence, can refresh the brain and does not have any side effect.